INDICATIONS FOR AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN HODGKINS-DISEASE

被引：17

作者：

CARELLA, AM ^{[1
]}

机构：

[1] OSPED SAN MARTINO GENOVA,DIV HAEMATOL 11,AUTOLOGOUS BONE MARROW UNIT,GENOA,ITALY

来源：

LEUKEMIA & LYMPHOMA | 1992年 / 7卷

关键词：

MARROW TRANSPLANTS; HODGKINS DISEASE;

D O I：

10.3109/10428199209061559

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This paper reviews briefly the most relevant indications for ABMT in Hodgkin's disease. The accurate definition of prognostic catagories at the time of first treatment failure and the role of ABMT in the early sequential treatment of highly effective drug combination followed by high dose chemotherapy in very high risk Hodgkin's disease patients, are also discussed. © 1992 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：21 / 22

页数：2

共 8 条

[1]

Armitage J.O., Bone Marrow Transplantation in the treatment of patients with lymphoma, Blood, 73, pp. 1749-1758, (1989)

[2]

Bonadonna G., Santoro A., Gianni M.A., Vivianti S., Siena S., Bregni M., Zucali R., Lombardi F., Bonfante V., Gianni L., Valagussa P., Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience, Ann. Oncol., 2, pp. 9-16, (1991)

[3]

Viviani S., Santoro A., Negretti E., Salvage chemothrapyin Hodgkin's disease. Results in patients relapsing more than twelve months after complete emission, Ann. Oncol., 1, pp. 123-127, (1990)

[4]

Sullivan K.M., Applelbaum F.R., Horning S.J., Rosenberg S.A., Thomas E.D., Section of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation, Int. J. Cell Cloning, 4, pp. 94-106, (1986)

[5]

Gribben J.G., Goldstone A.H., Linch D.C., Preliminary results of ABMT in the management of resistant Hodgkin's disease: Experience of the Bloomsbury Transplant Group at University College., 117, (1989)

[6]

Strauss D.J., Gaynor J.J., Myers J., Prognostic factors among 185 adult with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross resistant chemotherapy and intermediate-dose radiation therapy, J. Clin. Oncol., 7, pp. 1173-1181, (1990)

[7]

Carella A.M., Carlier P., Congiu A., Gaozza E., Occhini D., Meloni G., Anselmo A.P., Mandelli F., Mazza P., Tura S., Et al., Nine years experience with ABMT in 128 patients with Hodgkin's: An Italian Study Group Report, Fifth Inter. Symposium: Autologous BMT., pp. 509-518, (1991)

[8]

Carella A.M., Carlier P., Congiu A., Occhini D., Nati S., Pier-Luigi D., Giordano D., Bacigalupo A., Damasio E., Autologous BMT as adjuvant treatment for high-risk Hodgkin's disease in first remission after MOPP/ABVD protocol, Bone Marrow Transplantation, 8, pp. 99-103, (1991)

← 1 →